Racial and Ethnic Differences in County-Level Availability of Uterine Cancer Clinical Trials

Importance: Racial and ethnic disparities exist in clinical trial enrollment, but whether such disparities exist in geographic availability of uterine cancer trials is unknown. Objective: To examine associations between race and ethnicity and county-level presence and rates of available uterine cancer clinical trials. Design, Setting, and Participants: This retrospective cohort study linked Surveillance, Epidemiology, and End Results Research Plus; Aggregate Analysis of ClinicalTrials.gov; and American Community Survey data of adult patients (aged ≥18 years) diagnosed with uterine cancer between January 1, 2008, and December 31, 2021. The data analysis was performed between November 10, 2025, and September 9, 2026. Exposures: Race and ethnicity categorized as American Indian or Alaska Native, Asian, Black, Hispanic (any race), Native Hawaiian or Pacific Islander, and White. Main Outcomes and Measures: The main outcomes were county-level presence and rate of interventional uterine cancer trials. Hurdle models were used to estimate racial and ethnic differences in the odds of residing in a county with at least 1 trial and among patients in counties with trial availability, differences in rates of trials per person. Models accounted for county clustering and were adjusted for patient characteristics. Results: Among 155 811 patients in the cohort (median [IQR] age at diagnosis, 62 [55-69] years; 1055 identifying as American Indian or Alaska Native [0.7%], 12 753 as Asian [8.2%], 16 303 as Black [10.5%], 23 177 as Hispanic [14.9%], 2175 as Native Hawaiian or Pacific Islander [1.4%], and 100 348 as White [64.4%] race and ethnicity), 121 525 (78.0%) resided in a county with at least 1 available trial. Trial availability was observed among 58.0% of American Indian or Alaska Native patients, 94.3% of Asian patients, 77.7% of Black patients, 86.1% of Hispanic patients, 90.3% of Native Hawaiian or Pacific Islander patients, and 74.1% of White patients. Compared with White patients, higher odds of residing in counties with at least 1 available trial were found for Asian (odds ratio [OR], 5.83; 95% CI, 4.83-7.12), Black (OR, 1.18; 95% CI, 1.07-1.30), Hispanic (OR, 2.18; 95% CI, 1.80-2.63), and Native Hawaiian or Pacific Islander (OR, 3.34; 95% CI, 2.17-5.66) patients, whereas American Indian or Alaska Native patients had lower odds (OR, 0.49; 95% CI, 0.39-0.61). Among patients in counties with at least 1 trial, fewer available trials per person were found for Asian (rate ratio [RR], 0.69; 95% CI, 0.65-0.74), Hispanic (RR, 0.56; 95% CI, 0.52-0.61), and Native Hawaiian or Pacific Islander (RR, 0.87; 95% CI, 0.80-0.95) patients compared with White patients. Conclusions and Relevance: This cohort study of patients with uterine cancer found that racial and ethnic patterns in geographic trial availability differed by how availability was measured. The presence of any trial may not fully capture geographic access to clinical trial opportunities.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-13
DOI
https://doi.org/10.1001/jamanetworkopen.2026.44045
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Racial and Ethnic Differences in County-Level Availability of Uterine Cancer Clinical Trials

Ashley Sinclair Felix, Jeffrey J. Wing, Britton L. Trabert, Laura Chambers et al.
5 links
JAMA Network Open
Ethics in Clinical Research
article

Racial and Ethnic Differences in County-Level Availability of Uterine Cancer Clinical Trials

Ashley Sinclair Felix, Jeffrey J. Wing, Britton L. Trabert, Laura Chambers, Simran A. Kanal, Caitlin E. Meade, Jennifer Anne Sinnott
article en

Abstract

Importance: Racial and ethnic disparities exist in clinical trial enrollment, but whether such disparities exist in geographic availability of uterine cancer trials is unknown. Objective: To examine associations between race and ethnicity and county-level presence and rates of available uterine cancer clinical trials. Design, Setting, and Participants: This retrospective cohort study linked Surveillance, Epidemiology, and End Results Research Plus; Aggregate Analysis of ClinicalTrials.gov; and American Community Survey data of adult patients (aged ≥18 years) diagnosed with uterine cancer between January 1, 2008, and December 31, 2021. The data analysis was performed between November 10, 2025, and September 9, 2026. Exposures: Race and ethnicity categorized as American Indian or Alaska Native, Asian, Black, Hispanic (any race), Native Hawaiian or Pacific Islander, and White. Main Outcomes and Measures: The main outcomes were county-level presence and rate of interventional uterine cancer trials. Hurdle models were used to estimate racial and ethnic differences in the odds of residing in a county with at least 1 trial and among patients in counties with trial availability, differences in rates of trials per person. Models accounted for county clustering and were adjusted for patient characteristics. Results: Among 155 811 patients in the cohort (median [IQR] age at diagnosis, 62 [55-69] years; 1055 identifying as American Indian or Alaska Native [0.7%], 12 753 as Asian [8.2%], 16 303 as Black [10.5%], 23 177 as Hispanic [14.9%], 2175 as Native Hawaiian or Pacific Islander [1.4%], and 100 348 as White [64.4%] race and ethnicity), 121 525 (78.0%) resided in a county with at least 1 available trial. Trial availability was observed among 58.0% of American Indian or Alaska Native patients, 94.3% of Asian patients, 77.7% of Black patients, 86.1% of Hispanic patients, 90.3% of Native Hawaiian or Pacific Islander patients, and 74.1% of White patients. Compared with White patients, higher odds of residing in counties with at least 1 available trial were found for Asian (odds ratio [OR], 5.83; 95% CI, 4.83-7.12), Black (OR, 1.18; 95% CI, 1.07-1.30), Hispanic (OR, 2.18; 95% CI, 1.80-2.63), and Native Hawaiian or Pacific Islander (OR, 3.34; 95% CI, 2.17-5.66) patients, whereas American Indian or Alaska Native patients had lower odds (OR, 0.49; 95% CI, 0.39-0.61). Among patients in counties with at least 1 trial, fewer available trials per person were found for Asian (rate ratio [RR], 0.69; 95% CI, 0.65-0.74), Hispanic (RR, 0.56; 95% CI, 0.52-0.61), and Native Hawaiian or Pacific Islander (RR, 0.87; 95% CI, 0.80-0.95) patients compared with White patients. Conclusions and Relevance: This cohort study of patients with uterine cancer found that racial and ethnic patterns in geographic trial availability differed by how availability was measured. The presence of any trial may not fully capture geographic access to clinical trial opportunities.

JAMA Network OpenVol. 9(11)
University of Utah (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Huntsman Cancer Institute (US), The Ohio State University Wexner Medical Center (US), Wake Forest University (US), The Ohio State University (US)
Good health and well-being, Reduced inequalities
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon